UK regulatory authority MHRA approves Phase 1 trial with Cymerus™MSCs • World first clinical trial with allogeneic iPSC-derived product •
Major milestone for stem cell therapeutics and regenerative medicine •
Cements Cynata’s global leadership in second generation MSC therapeutics